Kymera Therapeutics Stock Forecast, Price & News

+0.89 (+1.53 %)
(As of 07/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume403,978 shs
Average Volume642,276 shs
Market Capitalization$2.66 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KYMR News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Kymera Therapeutics logo

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.14 out of 5 stars

Medical Sector

2131st out of 4,434 stocks

Biological Products, Except Diagnostic Industry

293rd out of 424 stocks

Analyst Opinion: 1.4Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Kymera Therapeutics (NASDAQ:KYMR) Frequently Asked Questions

Is Kymera Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kymera Therapeutics stock.
View analyst ratings for Kymera Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Kymera Therapeutics?

Wall Street analysts have given Kymera Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kymera Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Kymera Therapeutics?

Kymera Therapeutics saw a decrease in short interest in July. As of July 15th, there was short interest totaling 1,950,000 shares, a decrease of 17.4% from the June 30th total of 2,360,000 shares. Based on an average daily trading volume, of 493,100 shares, the days-to-cover ratio is currently 4.0 days. Currently, 6.7% of the shares of the stock are sold short.
View Kymera Therapeutics' Short Interest

When is Kymera Therapeutics' next earnings date?

Kymera Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Kymera Therapeutics

How were Kymera Therapeutics' earnings last quarter?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) issued its quarterly earnings results on Thursday, May, 6th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.09. The business had revenue of $18.70 million for the quarter, compared to analyst estimates of $21.13 million.
View Kymera Therapeutics' earnings history

What price target have analysts set for KYMR?

8 equities research analysts have issued 12 month price objectives for Kymera Therapeutics' shares. Their forecasts range from $35.00 to $80.00. On average, they anticipate Kymera Therapeutics' stock price to reach $56.50 in the next year. This suggests that the stock has a possible downside of 4.3%.
View analysts' price targets for Kymera Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Kymera Therapeutics' key executives?

Kymera Therapeutics' management team includes the following people:
  • Dr. Bruce L. Booth Ph.D., D.Phil., Co-Founder & Chairman (Age 47, Pay $26.53k)
  • Dr. Nello Mainolfi M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 42, Pay $832.62k)
  • Dr. Richard Chesworth Ph.D., Chief Scientific Officer (Age 51, Pay $447.88k)
  • Dr. Jared A. Gollob, Chief Medical Officer (Age 57, Pay $577.21k)
  • Mr. Bruce N. Jacobs CFA, Chief Financial Officer
  • Mr. Brian Albarran M.B.A., Ph.D., VP of Strategy & Operations
  • Mr. Michael J. Todisco, VP of Accounting & Fin. (Age 56)
  • Mr. Paul Cox, VP of Investor Relations & Communications
  • Ms. Karen Martin J.D., Ph.D., VP & Head of Legal
  • Ms. Paige Cochran, VP of HR

Who are some of Kymera Therapeutics' key competitors?

What other stocks do shareholders of Kymera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

When did Kymera Therapeutics IPO?

(KYMR) raised $126 million in an IPO on Friday, August 21st 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO.

What is Kymera Therapeutics' stock symbol?

Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR."

How do I buy shares of Kymera Therapeutics?

Shares of KYMR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kymera Therapeutics' stock price today?

One share of KYMR stock can currently be purchased for approximately $59.04.

How much money does Kymera Therapeutics make?

Kymera Therapeutics has a market capitalization of $2.66 billion and generates $34.03 million in revenue each year. The company earns $-45,590,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis.

How many employees does Kymera Therapeutics have?

Kymera Therapeutics employs 92 workers across the globe.

What is Kymera Therapeutics' official website?

The official website for Kymera Therapeutics is

Where are Kymera Therapeutics' headquarters?

Kymera Therapeutics is headquartered at 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472.

How can I contact Kymera Therapeutics?

Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The company can be reached via phone at 857-285-5300 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.